Discounted Cash Flow (DCF) Analysis Unlevered

Bone Biologics Corporation (BBLG)

$0.3165

-0.03 (-9.00%)
All numbers are in Millions, Currency in USD
Stock DCF: - | 0.3165 | undervalue

Operating Data

Year
A/P
2017
Projected
2018
Projected
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue ----------
Revenue (%)
EBITDA ----------
EBITDA (%)
EBIT ----------
EBIT (%)
Depreciation ----------
Depreciation (%)

Balance Sheet Data

Year
A/P
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Total Cash ----------
Total Cash (%)
Account Receivables ----------
Account Receivables (%)
Inventories ----------
Inventories (%)
Accounts Payable ----------
Accounts Payable (%)
Capital Expenditure ----------
Capital Expenditure (%)

Weighted Average Cost Of Capital

Share price $ 0.3,165
Beta 0.340
Diluted Shares Outstanding 2.91
Cost of Debt
Tax Rate -0.10
After-tax Cost of Debt 5.00%
Risk-Free Rate
Market Risk Premium
Cost of Equity 5.098
Total Debt -
Total Equity 0.92
Total Capital 0.92
Debt Weighting 0.00
Equity Weighting 100.00
Wacc

Build Up Free Cash

Year
A/P
2017
Projected
2018
Projected
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue ----------
EBITDA ----------
EBIT ----------
Tax Rate -0.02%-0.04%-0.05%-0.09%-0.10%-0.06%-0.06%-0.06%-0.06%-0.06%
EBIAT ----------
Depreciation ----------
Accounts Receivable ----------
Inventories ----------
Accounts Payable ----------
Capital Expenditure ----------
UFCF ----------
WACC
PV UFCF ----------
SUM PV UFCF -

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) 5.10
Free cash flow (t + 1) -
Terminal Value -
Present Value of Terminal Value -

Intrinsic Value

Enterprise Value -
Net Debt -0
Equity Value -
Shares Outstanding 2.91
Equity Value Per Share -